Back to search
FDAFDA · Food and drugs·Recall number D-0260-2021

Auryxia (ferric citrate) tablets, 210 mg*, 200 tablets bottle, RX ONLY, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., 245 First Street, Suite 1400, Cambridge, MA 02142, USA, NDC 59922-0631-01.

Published February 24, 2021 · Recall initiated: January 29, 2021

Summary

FDA records drug Class III recall D-0260-2021, published February 24, 2021 and initiated January 29, 2021. Recalling firm: Akebia Therapeutics dba Keryx Biopharmaceutials, Inc; Status: Terminated; Reported quantity: 17,664 bottles; Lot: Lots #: CDKSN, CDPPH, Exp January 2022; Lot #: CDPPK, Exp February 2022. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Akebia Therapeutics dba Keryx Biopharmaceutials, Inc
Distributor
Nationwide.
Lot
Lots #: CDKSN, CDPPH, Exp January 2022; Lot #: CDPPK, Exp February 2022.
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Auryxia (ferric citrate) tablets, 210 mg*, 200 tablets bottle, RX ONLY, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., 245 First Street, Suite 1400, Cambridge, MA 02142, USA, NDC 59922-0631-01. recalled?

Yes. FDA published recall D-0260-2021 on February 24, 2021. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter